🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
INCY
NASDAQ
🇺🇸 US
Incyte Corp.
Pharmaceuticals
31Score
DipBuster Score™
$120.39
+$3.59 (+3.07%)
Live price · Source: Yahoo
52-Week Position
$89.25
72% of range
$132.60
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
BetaN/A
52W High$132.60
52W Low$89.25
DipBuster Brief
Key signals at a glance
Zone: Consider Trimming
Neutral
Mid-Range Position (72% of 52-Week Range)
The stock sits in the middle of its annual range — no extreme dip opportunity, but also not overextended.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position72% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta—
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Incyte Corp. (INCY), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-10-01 | Heeson Lee | SELL | 463 |
| 2026-09-30 | Clancy Paul J | BUY | 203 |
| 2026-09-30 | Harrigan Edmund | BUY | 206 |
| 2026-09-30 | Baker Bros. Advisors Lp | BUY | 322 |
| 2026-09-30 | Baker Bros. Advisors Lp | BUY | 322 |
| 2026-09-22 | Gardner David H | SELL | 920 |
| 2026-09-15 | Cagnoni Pablo J | SELL | 9,233 |
| 2026-09-15 | Cagnoni Pablo J | SELL | 6,477 |
| 2026-09-15 | Cagnoni Pablo J | SELL | 4,551 |
| 2026-09-15 | Cagnoni Pablo J | SELL | 2,957 |
Graham NCAV Analysis
Above net-net level
Current Assets$5.02B
Less: Total Liabilities−$1.79B
= Net Current Asset Value$3.23B
NCAV Per Share$16.2925
Current Price$120.39
Price / NCAV7.39×
Margin of Safety-638.9%
Computed from 2025-12-31 balance sheet (Yahoo Finance). NCAV = current assets − total liabilities. Verify against the latest report.
Valuation
P/E RatioN/A
Market CapN/A
BetaN/A
Dividend/yrNone
52W High$132.60
52W Low$89.25
52-Week Range
$89.25Now$132.60
72% through annual range
From 52W High−9.2%
From 52W Low+34.9%
📖 Plain English Summary
Incyte Corp. is at 72% of its 52-week range.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for INCY
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — INCY
Heuristic · balance sheet, insider filings, price data, academic research
Incyte Corp. — DipBuster Score 31/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Incyte Corp. free
Add INCY to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Trading 212
Commission-free investing. ISA and GIA available. FCA regulated.
Free share worth up to £100 when you sign up
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
11/25
Momentum & Volume
15/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
2
/100 · NEUTRAL
dip depth
2/25
oversold rsi
0/25
mean reversion
0/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 31/100
📈
Strong recent momentum — price and volume trending in the right direction.